P1052 Ustekinumab for refractory intestinal Behçet’s Disease
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjae190.1226
Abstract: Intestinal Behçet’s disease (BD) is typically treated with a limited number of empirical medications. There is a continuing need for more effective and safer treatment options, particularly for refractory cases. This study reports the first… read more here.
Keywords: refractory intestinal; treatment; intestinal beh; disease ... See more keywords